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Abstract 
Circadian rhythms are recurring cycles across a range of behavioural, 
physiological and cognitive domains that display periods of approximately 
twenty four hours and are generated by an endogenous circadian timing 
system. In this review we examine the evidence that circadian rhythms are 
disrupted in affective disorders such as major depression, bipolar disorder 
and seasonal affective disorder, and examine what the nature of such 
circadian dysfunction may be.  Further, we examine the evidence that 
chronotherapeutic interventions (both behavioural and pharmacological) 
that address underlying abnormalities of circadian phase in patients with 
affective disorders may produce rapid onset and long-lasting symptom 
relief. We conclude that there is promising data in the literature to support 
the utility of drawing on a considerable body of neuroscientific knowledge 
of circadian clock fundamentals to design and implement chronotherapeutic 
interventions in major affective disorders, but that there is also a need for a 
more systematic approach involving larger scale studies. 
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Introduction to the circadian system 
A most striking finding across a range of common psychiatric conditions 
is the high rates of co-morbid sleep disturbances.  For example, co-morbid 
insomnia, as defined by the DSM-IV criteria for secondary insomnia, is present in 
37% of those with a diagnosis of schizophrenia (Xiang et al, 2008), 41% in major 
depression (Stewart et al, 2006), 24% in the euthymic phase of bipolar disorder 
(Brill, Penagaluri, Roberts, Gao, & El-Mallakh, 2011) and 27% in adult attention 
deficit hyperactivity disorder (Schredl, Alm, & Sobinski, 2011).  Indeed, when 
one examines the rates of sleep disturbances that are sub-threshold for a diagnosis 
of insomnia, or sleep disturbances such as hypersomnias, these are found to occur 
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in the vast majority of such patients.  For example, in major depression the rates 
of sleep dysfunction is 90% (Breslau, Roth, Rosenthal, & Andreski, 1996) leading 
to the contention that sleep dysfunction should not be considered a co-morbid 
condition of major depression, and rather should be viewed as a core symptom 
(Mendlewicz, 2009). 
 Out of these striking findings arises the fundamental question of why 
there is this very close link between such conditions and sleep disturbances. Aside 
from the numerous unanswered questions about the aetiology of common 
psychiatric conditions, we may look towards what is known about the regulation 
of sleep for clues.  Borbely (1982) proposed the two process model of sleep-wake 
control, where the drive towards sleep or wakefulness is determined by the 
interaction of two processes, the homeostatic process (process S) and the 
circadian process (process C).  It is to the circadian regulation of the sleep-wake 
cycle that we will concern ourselves in this review, as there is considerably 
greater mechanistic insight into this over homeostatic processes, but we will also 
consider the important interplay between these two key processes (for example in 
considering the anti-depressant effects of sleep deprivation). 
 Circadian rhythms are recurring cycles that display periods of about 
twenty four hours, and are manifested across a range of behavioural, 
physiological and cognitive processes (Cagampang and Bruce, 2012; Valdez, 
Ramirez,& Garcia, 2012). These rhythms are driven by an endogenous circadian 
timekeeping system, and persist in the absence of environmental time cues 
(Reppert & Weaver, 2002). At a systems level, the master circadian pacemaker is 
located to the suprachiasmatic nuclei (SCN) of the ventral anterior hypothalamus 
(Ralph, Foster, Davis, & Menaker, 1990).  There are also a large number of 
central and peripheral sites that possess autonomous or semi-autonomous 
circadian clocks as well (Guilding & Piggins, 2007; Dibner, Schibler & Albrecht, 
2010), and as such the circadian timing mechanism as a whole functions as a 
highly complex, distributed and hierarchical system with communication and 
transmission of phase information between component parts a key factor in the 
maintenance of appropriate biological time in an organism. As the nature of the 
circadian system is that it maintains time on a near daily basis, in order for 
internal biological time to match appropriate environmental cycles, the circadian 
system must be entrainable to appropriate environmental time cues (zeitgebers).  
In mammals, including humans, the dominant zeitgeber is light. The principal 
neural pathway through which light information is passed to the circadian system 
is via the retinohypothalamic tract, a glutamatergic projection arising from 
specialised photoreceptive retinal ganglion cells that directly innervates the SCN 
(as well as other brain areas involved in non-visual pathways; Baver, Pickard, 
Sollars, & Pickard, 2008). Through this pathway photic stimulation can alter 
circadian phase and ensure appropriate synchronisation between the internal 
pacemaker and the light/dark cycle of the environment. It appears that appropriate 
entrainment of the clock may be a key component in ensuring both mental and 
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physical health and wellbeing.  We shall discuss later the evidence that 
misalignment of circadian phase may be a key component in mood disorders,  but 
it is worth noting here that such influences may also impinge on metabolic 
processes (Wyse, Selman, page, Coogan, & Hazlerigg, 2011) and even on 
longevity (Wyse, Coogan, Selman, Hazlerigg, & Speakman, 2010). 
 Another key component of the circadian system is the pineal hormone 
melatonin.  In mammals the production of melatonin is gated through the SCN, 
via the paraventricular nucleus of the hypothalamus, the sympathetic ganglion 
chain (superior cervical ganglion) and the release of noradrenaline onto β-
adrenoreceptors expressed on pinealocytes which drives the biosynthesis of 
melatonin.  Melatonin may then act through its G-protein-coupled MT1 and MT2 
receptors in various central and peripheral sites.  For example, cells of the SCN 
express MT1 and 2 receptors, are responsive to melatonin and exogenous 
melatonin can alter circadian phase (Lewy, Emens, Jackman, & Yuhas, 2006).  
Therefore melatonin signal may serve in part to feedback onto the SCN. Light 
suppresses melatonin biosynthesis, and therefore melatonin is usually produced 
during the lights off phase, with production starting in humans normally around 
9pm and reaching a peak about 3am. Given that under dim-light conditions that 
melatonin biosynthesis is gated by the SCN clock, the time of melatonin onset 
under such circumstances (the dim light melatonin onset, or DLMO) is found to 
be a reliable indicator of internal circadian phase in human studies (Pandi-
Perumal et al, 2007). Melatonin is not the only hormone under substantial 
circadian regulation, with other factors such as prolactin, vasopressin, and 
corticosteroids all showing classical circadian rhythms of secretion (Kalsbeek et 
al, 2006). Corticosteroids seem particular strongly linked with the circadian 
system, both in terms of the temporal control the SCN clock exerts on their 
production via the hypothalamic-pituitary-adrenal axis and also in terms of their 
ability to alter circadian processes in target tissues (Dibner et al, 2010).  
 With regards to the molecular mechanisms by which circadian rhythms 
are generated, it is known that the core processes involve a panel of “clock 
genes”, which form a series of interlocking feedback/feedforward loops that 
regulate their own expression on a near twenty four hour basis (Dibner et al, 
2010). Core components of this circadian clock gene cycle include PER1, PER2, 
PER3, CLOCK, BMAL1, CRY1, CRY2 and REV-ERB-α. The essential nature of 
this timekeeping mechanism, based on transcriptional feedback loops, seems well 
conserved, with clock gene cycles demonstrated in lower order organisms such as 
fungi and yeast (Dibner et al, 2010). In essence, the clock gene cycle works on the 
basis of CLOCK and BMAL1 forming a heterodimer, which in turn binds to E-
box elements on the promoter sequences of per and cry genes.  This drives the 
transcription of these genes, whose protein products then dimerise themselves and 
re-enter the nucleus to suppress the transcriptional activation abilities of the 
CLOCK:BMAL1 complex.  Further, there is another feedback loop in which  
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Rev-erb α and RORa have their expression driven by CLOCK:BMAL1, and in 
turn regulate the transcription of bmal1 (Dibner et al, 2010). The cycling of these 
core clock genes also in turn drives the rhythmic regulation of clock-controlled 
genes, the identity of which appears to be regulated in a tissue specific manner.  
The influence of the circadian clock on the transcriptional landscape appears to be 
extensive and highly complex and result in between 10%-20% of transcripts 
showing circadian regulation in any given tissue (Panda et al, 2001; Koike et al, 
2012). It is thought that it is through such regulation of clock controlled genes that 
rhythmic changes in behaviour and physiology subsequently arise. 
The tracking of daily patterns of clock gene expression has allowed for 
the identification of a number of central nervous sites outside of the SCN as 
displaying such daily patterns (Guilding & Piggins, 2007).  A number of such 
sites, for example the hippocampus, the amygdala, the basal forebrain and 
cerebral cortex, are all also long implicated in the pathophysiology of mood 
disorders. Although it is not fully appreciated what physiological role that these 
clock gene cycles may play in each central nervous site it can be shown that 
disruption of these cycles leads to various behavioural and cognitive impairments 
in experimental animal studies (Jilg et al, 2010; Loh et al, 2010). 
   
Evidence for the involvement of circadian rhythms in mood disorders 
The observation that abnormal circadian rhythms may be manifest in 
patients with mood disorders were first reported nearly fifty years ago (Elithorn, 
Bridges, Lobban, & Tredre 1966; Halberg, Vestergaard, & Sakai, 1968). Since 
then there have been numerous studies that have sought to characterise the nature 
of circadian disturbances that are associated with different mood disorders. 
Overall, there is an unfortunate lack of cohesiveness in the literature on this 
subject.  There are many studies that point towards biological rhythm disruption 
in mood disorders, but many of these are seriously underpowered and there are 
too frequent methodological differences in the approaches adopted to allow for 
meaningful meta-analysis. Having said this, the majority of published studies do 
indicate that there are often phase abnormalities of circadian rhythms associated 
with mood disorders, perhaps indicating a failure of the normal processes of 
entrainment of the circadian system to appropriate environmental zeitgebers, 
leading to a state of internal desynchronisation, for example between the sleep 
cycle and the circadian cycle.  In major depression there are reports that circadian 
rhythms are either phase-advanced or phase delayed, or neither (van der 
Hoofdakker, 1994; Robillard et al, 2009; Emens, Lewy, Kinzie, Arntz, & Rough, 
2009; Hasler, Buysse, Kupfer, & Germain, 2010). It may be that there are a subset 
of individuals with affective symptoms that express circadian changes, and then a 
population with affective disorders who do not display circadian abnormalities.  
Certainly, it seems that circadian misalignment on its own is not sufficient to 
cause depression, as evidenced by the lack of association of depression with shift 
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work, in contrast to many common chronic medical conditions (Vogel, 
Braungardt, Meyer, & Schneider, 2012). Another important factor may be age: 
young subjects with depression may display different changes in circadian 
rhythms compared to older subjects (Tsujimoto, Yamada, Shimoda, Hanada, & 
Takahashi, 1990), and it is known that normal healthy aging exerts considerable 
influence on the circadian system (Weinert, 2000). There are a number of studies 
that have indicated that depression is associated with a shift of chronotype 
towards evening preference (Chelminski, Ferraro, Petros, & Plaud, 1999; 
Kitamura et al, 2010) and evening preference is associated with phase delayed 
circadian rhythms (Mongrain, Carrier, & Dumont, 2006). 
  Interestingly a couple of small studies have indicated that depressive 
symptom severity in non-seasonal depression is correlated to the phase 
misalignment of the circadian rhythm (Emens et al, 2009; Hasler et al, 2010), and 
correlations between symptom severity and circadian parameters have been 
reported in other psychiatric conditions, such as attention deficit hyperactivity 
disorder (Baird, Coogan, Siddiqui, Donev, & Thome 2012). However, there are 
significant issues concerning study heterogeneity (sex, age, diagnosis, 
psychopharmacology) and study methodology (which subjective and/or objective 
measures are used to determine circadian phase, field or laboratory based studies, 
issues of statistical power) that will need to addressed in future larger studies in 
order to gain a systematic insight into the nature of circadian changes that occur 
in major depression.  
There is also evidence for circadian rhythm disturbance in bipolar 
disorder (BPD). Salvatore et al (2008), using wrist actigraphy, describe significant 
advances of the daily activity rhythm in BPD-I patients both in their euthymic and 
manic/mixed phases.  Jones, Hare, & Evershed (2005) also report findings from 
actigraphy in BPD patients.  These authors describe less robust and more 
inconsistent rhythms in BPD patients compared to controls, although they did not 
examine acrophase of these rhythms to test for any underlying phase shift.  These 
circadian changes were present when the patients were not acutely ill. These 
studies seem to complement findings from earlier studies of rhythms in bipolar 
patients (eg. Kupfer, Weiss, Foster, Detre, & McPartland, 1974; Wehr, 
Muscettola, & Goodwin, 1980) and suggest that circadian dysfunction may be a 
trait characteristic of BPD. Yang, Van Dongen, Wang, Berrettini, & Bucan (2009) 
examined what might be the underpinning mechanism of such circadian rhythm 
abnormalities in BPD by examining the rhythmic expression of clock genes in 
fibroblasts obtained from BPD patients and controls. They report that there were 
changes in the amplitude of the rhythms for the clock gene BMAL1 and the clock-
controlled output gene DBP. Since circadian phase is understood to be determined 
by the interaction of circadian period and amplitude (Brown et al, 2008) these 
described changes in clock gene rhythm amplitude may be a contributing factor to 
altered circadian phase observed in BPD. 
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Seasonal affective disorder (SAD), also known as winter depression, is a 
form of depression usually associated with onset of symptoms in the 
autumn/winter (although symptoms may have their onset at different times of the 
year), with symptoms then remitting but recurring with a similar temporal pattern 
in following years (Westrin & Lam, 2007). SAD is also associated with atypical 
neurovegative symptoms such as increased appetite (particularly for 
carbohydrates) and resultant weight gain, hypersomnia and fatigue.  The picture 
of symptom onset associated with seasonal change and atypical symptoms in 
physiological parameters that normally show strong circadian control has lead to 
the postulation that a deficit in circadian resetting at season change may underpin 
the aetiology of SAD.  This change may be triggered by longer nights and hence a 
change in the duration of the melatonin signal during winter, by the later onset of 
dawn as a  key zeitgeber, or by a combination of these (Levitan, 2007). A seminal 
study by Lewy, Lefler, Emens, & Bauer (2006) report that there was a correlation 
between SAD ratings and desynchronisation between sleep and circadian cycles, 
and that further 71% of SAD patients in the study had phase delayed rhythms and 
29% had phase advanced rhythms. Regression analysis revealed that the 
DLMO/midsleep relationship used in the study to account for circadian phase 
shifts accounted for 17% of the variance in SAD ratings.   These results indicate 
that there is a substantial subpopulation of SAD patients that display advanced 
rhythms, and that it may be the presence of a phase shift, rather than the direction 
of that phase shift (delayed vs. advanced) that may be prescient in determining the 
circadian basis of SAD.  
Another area in which there are consistent findings is the examination of 
chronotype in affective disorders, and indeed in other common psychiatric 
conditions.  There are numerous reports that affective disorders are associated 
with a shift towards greater eveningness, and eveningness is also associated with 
increased impulsivity and risk taking and novelty seeking, all traits associated 
with psychoticism (reviewed in Adan et al, 2012). It is not fully understood which 
factors make up chronotype: there certainly appears to be a biological basis for 
this phenomenon in circadian clock characteristics in individuals (Brown et al, 
2008), but environmental factors, such as increased nocturnal light exposure 
which may phase-shift the clock, are also likely to be key contributing factors in 
determining chronotype (Adan et al, 2012).  Therefore, an intrinsic phase delay in 
depression may itself lead to move nocturnal activity and light exposure, which in 
turn could reinforce the evening orientation associated with affective disorders. 
An interesting and important facet that is very relevant for understanding 
the chronobiology of mood disorders is how affect is regulated on a daily basis. 
Non clinical populations show daily variation of affect, with positive affect 
showing a circadian rhythm with a nadir at the time of the trough of body 
temperature, whilst negative affect did not display a rhythm (Murray, Allen, & 
Trindler, 2002). Boivin et al (1997) demonstrated under forced desynchrony 
(allowing for the separation of circadian and sleep/wake components) that affect 
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displays a circadian regulation, but is also sensitive to prior wakefulness in a 
circadian time-dependent mechanism. Another study using textual analyses of 
millions of social media messages have shown peaks of positive affect in the 
morning across a number of cultures, with negative affect increasing as the day 
wears on, and these patterns persist at the weekends but are delayed, perhaps 
reflecting the opportunity to “lie in” (Golder & Macy, 2011).  In clinical 
populations there are studies which have reported a delay of the peak of lowest 
mood in major depression, so that it occurs during the early morning (Von 
Zerssen et al, 1985), and under a forced desynchrony protocol in patients with 
SAD mood in the patient and control groups both showed circadian and 
sleep/wake control (Koorengevel, Beersma, den Boer, & van den Hoofdakker, 
2003). On a molecular basis the monoamine oxidase A gene, intimately 
implicated in mood, is found to regulated by the core mechanisms of the circadian 
clock, thus offering one mechanism through which affect may be under circadian 
control (Hampp et al, 2008). Overall, affect appears to be sensitive to both 
circadian and sleep/wake cycle control, and the interaction between these is vital.  
Therefore, any circadian misalignment with the sleep/wake cycle that may 
accompany mood disorders may impact on this and contribute to the labiality of 
mood in these conditions. 
As we consider circadian changes that appear to occur in mood disorders, 
we are inevitably left with the “chicken and egg” question of do circadian 
abnormalities contribute to the aetiology of these conditions, or whether circadian 
rhythms become disturbed as a secondary effect of the sympatomatology of these 
conditions, or a combination of the two?  Given the fundamental gaps in our 
understanding of the aetiology of such conditions, this is a question that is not 
possible to address in any satisfactory way based on current evidence. There have 
been a number of studies examining the association of polymorphisms in 
circadian clock genes and mood disorders, and these studies have demonstrated 
various significant associations (reviewed in Partonen, 2012).  Such studies are 
somewhat hindered by sufficient lack of power (for example there are no 
published genome wide studies of SAD), as well as the issue of lack of 
knowledge of the functional consequences on many such polymorphisms on these 
genes’ protein products, but they do indicate that circadian factors may be of 
significance in the aetiology of mood disorders. To help further address these 
issues there is a need for meaningful prospective studies.  Ritter et al (2012) have 
recently described that subjects being at high risk of developing BPD show some 
sleep and activity changes compared to controls. Ankers & Jones (2009) also 
report circadian rhythm changes in individuals at high risk of developing BPD.  
Such promising findings should lead to the inclusion of measures of circadian 
rhythms in large cohort prospective studies.  Such approaches have recently 
shown that altered circadian timing is a significant predictor for subsequent mild 
cognitive impairment or dementia (Tranah et al, 2011).  
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Chronotherapy of affective disorders 
 As outlined above, there is reasonable evidence that circadian dysfunction 
accompanies major affective disorders, and that such dysfunction may in part 
contribute to the aetiologies of these conditions. The principal component of these 
circadian dysfunctions seems to revolve around inappropriate phase shifts leading 
to internal desynchronisation.  This is in contrast to other neurological conditions, 
such as dementias, in which the principal circadian abnormalities appear to be in 
the realm of decreased rhythm amplitude (Coogan et al, 2012). In order to address 
these phase misalignments, and to produce clinical benefit by resynchronising 
rhythms, we can draw on an extensive literature on phase-shifting of the circadian 
clock.  It is known that presentation of light stimuli will produce phase shifts of 
the human circadian system, and the nature of these shifts (eg. advances versus 
delays) will  depends on the point in the endogenous circadian cycle in which 
they are presented (Revell, Molina & Eastman, 2012). Other non photic 
manipulations can also induce phase shifts of circadian rhythms – for example 
exogenous melatonin or melatoninergic agonists (Lewy & Sack, 2006).  Indeed, 
compounds such as serotonin/and or noradrenaline reuptake inhibitors that are 
used as antidepressants can also induce phase shifts in animal models (Gannon & 
Millan, 2007; O’Keeffe, Thome, & Coogan, 2012). So application of core 
neuroscientific knowledge regarding mechanism of phase shifting might be 
applied fruitfully in the clinic (Benedetti, Barbini, Colombo, & Smeraldi, 2007). 
 To date most attention has focussed on the application of 
chronotherapeutics in SAD, due to the strong implication of the circadian system 
in the aetiology of this condition.  Most studies have utilised bright light therapy, 
involving exposure to white light (usually 5,000-10,000 lux)  for 30-60 minutes 
each day, usually aimed at the morning (to produce phase advances) or sometimes 
in the evening (to produce phase delays). In the SAD literature, there had been 
descriptions that light therapy was associated with significant remission rates, and 
in general morning light was associated with better outcomes than evening light, 
although some studies did report benefit of evening light on SAD ratings 
(Terman, Schlager, Fairhurst, & Perlman, 1989; Lewy et al, 1998).  A plausible 
explanation for these apparent discrepancies is the finding of Lewy et al (2006) 
that the majority of SAD patients show a delay of their DLMO in relation to 
midsleep, whilst a significant minority demonstrated an advance. In terms of 
chronotherapy of SAD, these authors then demonstrated a pairing of morning 
light and evening melatonin to induce phase advances in SAD patients with phase 
delays produced diminution of SAD symptom, as did phase delaying morning 
melatonin and evening light for those patients with a SAD-related phase advance 
(decrease in SAD ratings of 34% for the correct-intervention groups versus 13-
15% for the control groups).  However, when the inappropriate intervention is 
applied (eg. phase-delaying stimulus to patients with a pre-existing phase delay) 
there is no resulting significant improvement in SAD scores, indicating that 
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ascertaining the underlying phase-misalignment in SAD patients is critical in 
selecting the optimal chronotherapeutic approach. Other more naturalistic 
approaches to light treatment in SAD, for example dawn simulation, also appear 
effective in producing phase shifts (Terman & Terman, 2010), whilst the use of 
blue light (the wavelength of light to which the circadian system is maximally 
sensitive to; Revell et al, 2012) may allow for lower light intensities and resulting 
better compliance (Meesters, Dekker, Schlangen, Bos, & Ruiter, 2011).   
 In the treatment of non seasonal major depression and bipolar disorder 
chronotherapeutic interventions also show promise. Studies have used 
combinations of light therapy, changes of scheduled sleep timing, melatonin and 
sleep deprivation as interventions.  Total sleep deprivation has long been 
described as exerting a rapid anti-depressant action in depressed patients, 
although the usefulness of such an approach has historically been limited by the 
short duration of these effects (Bunney & Bunney, 2012). However a number of 
studies have shown that combining total sleep deprivation with melatonin and/or 
light therapy produces significant and enduring symptom amelioration.  Benedetti 
et al (2007) demonstrated that in BPD patients suffering depressive episodes 
application of a six day regime of 3 days of total sleep deprivation combined with 
morning light therapy produced significant relief of depression in two thirds of 
patients (a decrease in the Hamilton Depression Rating Scale of ~70% compared 
to ~30% in non-responders), and this effect was correlated with the phase advance 
produced by the intervention (eg. responders showed a significant advance and 
decreases in depression ratings, non-responders did not show significant phase 
shifts or symptom relief). Wu et al (2009) demonstrate that such approaches can 
produce enduring symptom relief.  These authors applied a regime of sleep 
deprivation, light therapy and advances of sleep time to BPD patients in addition 
to their normal medication, and demonstrated that the chronotherapy-augmented 
group showed significant reductions in depression ratings that persisted over the 
seven weeks these patients were followed for compared to the control group on 
their normal medication alone (decrease in the Hamilton Scale scores of ~50% for 
the chronotherapy group compared to ~25% for the treatment as usual group). 
These results indicate that chronotherapy can effectively be applied in 
conjunction with treatment-as-usual to significant clinical benefit.  Moscovici & 
Kotler (2009) trialled a chronotherapeutic approach comprising of light therapy, 
sleep advances and partial sleep deprivation in a small population of patients with 
major depression.  This intervention produced significant lessening of depression 
ratings (~70% reductions in clinician scored ratings, no control group) that 
persisted over the 30 days of the study, again pointing to the potential for wider 
use of such protocols. A study in drug-resistant depression using a six day 
protocol of total sleep deprivation, sleep advance and light therapy has 
demonstrated a rapid onset alleviation of depression (~ 50% reduction in the 
Hamilton score, again no control group in this study) that persisted for the twenty 
days of the study (Echizenya, Suda, Takeshima, Inomata, & Shimizu, 2013). 
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From a mechanistic point of view it is not known how sleep deprivation may 
exert its antidepressant effects although these may be in part mediated via 
manipulation of the circadian system (Bunney & Bunney, 2012).  For example, 
Antle & Mistlberger (2000) report that in hamsters sleep deprivation phase 
advances the circadian clock, raising the possibility that a similar mechanism 
might be at play in humans.  
 Another area of considerable interest is in pharmacological 
chronotherapeutics. To date most attention has been directed towards agents that 
act on the melatoninergic system.  The most significant of these is agomelatine, a 
drug approved by the European Medicines Agency for the treatment of 
depression.  Agomelatine was initially designed as an agonist for MT1 and MT2 
melatonin receptors, but also has antagonist actions at the 5HT-2C receptor 
(deBodinat et al, 2010).  Clinical trials show that agomelatine may have 
significant benefit for the treatment of depression (Kasper et al, 2013; Laux et al, 
2012), is well tolerated and appears to have a favourable side-effect profile, 
although there may be issues with regards to hepatotoxicity (Carney & Shelton, 
2011). For example, the study of Laux et al (2012) report a decrease in the 
MADRS score of ~60%, and 65% of patients were responders and 55% were 
remitters.  In a pooled analysis of 4 studies over six months Demyttenaere et al 
(2013) report remission rates of ~ 60% compared to ~50% for SSRIs. 
Agomelatine appears to confer significant benefit for insomnia comorbid with 
depression, and it may be that this drug is best suited to the treatment of the (not 
insubstantial) specific populations of depressed patients with significant insomnia 
and other sleep disturbances (Srinvassan et al, 2012). It has been shown that, as 
might be expected for a short acting melatoninergic agonist, that agomelatine 
alters circadian rhythms.  For example, early evening administration of 
agomelatine appears to phase advance a number of endocrine diurnal rhythms 
(LeProult et al, 2005).  This would suggest that part of agomelatine’s mode of 
action is via resynchronisation of circadian rhythms.  However, if this is the case 
then the timing of the dose of agomelatine and the underlying circadian 
characteristic of any given patient may well determine whether maximal efficacy 
is achieved.  Therefore, there may be a need for chronodiagnostics before the 
appropriate chronotherapy might be applied. Other melatoninergic agonists, such 
a ramelteon, may also have clinical benefits.  In a recent study Norris et al (2013) 
describe that ramelteon significantly decrease relapse rate in BPD patients. It is to 
be hoped that well constructed (including chronobiological consideration), well 
powered future trials will further point towards the potential to produce 
antidepressant effects via manipulation of the circadian/mealtoninergic system. 
 
Considerations and future directions 
 There is reasonable evidence in the literature that dysregulation of the 
circadian timing system occurs in affective disorders, that such dysregulation may 
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contribute to the psychopathology of these conditions directly or indirectly via co-
morbid conditions (eg. insomnia), and that addressing these circadian 
dysregulations appears to produce rapid and significant clinical benefit.  
However, there are a number of important areas that need to addressed.  First is 
the requirement for multilevel assessment of circadian rhythms in clinical 
population in large studies in order to systematically define the nature of circadian 
disturbances in affective disorders.  Multilevel assessments are required to 
understand the nature of whatever internal desynchronisation may take place (eg. 
between DLMO and midsleep, or DLMO and core body temperature).  There are 
too many examples of small/pilot type studies in the literature that provide 
interesting sign posts but make it impossible to draw definitive conclusions. On 
the chronotherapeutics front, there is also a need for larger studies, as well as a 
need to undertake some type of chronophenotyping of study subjects to allow for 
the apparently maximally effective strategy to be used.  The blanket application of 
say morning light therapy may only benefit a subset of study subjects who have 
an underlying phase delay, but not those who may already be phase advanced.  
There is also the intriguing question as to whether current treatments (either 
pharmacological or psychotherapeutic) that produce relief of depression also 
produce changes in circadian rhythms?  There is also the question as to if an 
effective psychotherapeutic approach based on addressing circadian dysfunction 
might be developed as has been successful in the treatment of insomnia?   
Overall, chronobiology provides us with many opportunities to build on 
our considerable neuroscientific understanding of the circadian system to produce 
novel and meaningful interventions to relieve the burden of suffering from the 
millions worldwide who suffer from affective disorders. 
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